非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2022-02-28), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (美国)、突破性疗法 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、优先药物(PRIME) (欧盟)、优先审评 (中国)、突破性疗法 (中国)、特殊审批 (中国)、孤儿药 (韩国)、附条件批准 (欧盟)、孤儿药 (英国)、附条件批准 (中国) |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
多发性骨髓瘤 | 美国 | 2022-02-28 | |
多发性骨髓瘤 | 美国 | 2022-02-28 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
复发性多发性骨髓瘤 | 临床3期 | 美国 | 2020-06-12 | |
复发性多发性骨髓瘤 | 临床3期 | 日本 | 2020-06-12 | |
复发性多发性骨髓瘤 | 临床3期 | 澳大利亚 | 2020-06-12 | |
复发性多发性骨髓瘤 | 临床3期 | 比利时 | 2020-06-12 | |
复发性多发性骨髓瘤 | 临床3期 | 丹麦 | 2020-06-12 | |
复发性多发性骨髓瘤 | 临床3期 | 法国 | 2020-06-12 | |
复发性多发性骨髓瘤 | 临床3期 | 德国 | 2020-06-12 | |
复发性多发性骨髓瘤 | 临床3期 | 希腊 | 2020-06-12 | |
复发性多发性骨髓瘤 | 临床3期 | 以色列 | 2020-06-12 | |
复发性多发性骨髓瘤 | 临床3期 | 意大利 | 2020-06-12 |
临床3期 | 419 | Ciltacabtagene autoleucel (cilta-cel) (pts with extramedullary disease (EMD) | 衊膚觸顧憲淵構膚積遞(製簾壓鏇壓遞淵繭獵淵) = 窪餘繭製襯繭憲廠願齋 壓夢獵淵膚窪醖鏇膚遞 (窪製壓鹹獵襯膚糧壓網 ) 更多 | 积极 | 2025-05-30 | ||
Standard of Care (SOC) (pts with extramedullary disease (EMD) | 衊膚觸顧憲淵構膚積遞(製簾壓鏇壓遞淵繭獵淵) = 壓憲襯製獵膚壓壓獵鬱 壓夢獵淵膚窪醖鏇膚遞 (窪製壓鹹獵襯膚糧壓網 ) 更多 | ||||||
临床1/2期 | 复发性多发性骨髓瘤 hemoglobin | platelets | effector-to-target ratio | 97 | 鹽艱廠遞憲淵製窪壓衊(遞鏇繭遞積鹽醖衊製醖) = 網鹹餘鑰鹽鏇襯積遞憲 鑰鬱網觸觸淵襯製壓襯 (醖窪製齋鹹窪繭齋齋鑰, 41.9 ~ NE) 更多 | 积极 | 2025-05-30 | ||
N/A | 140 | (Patients with CNP) | 壓築簾壓淵積簾齋夢鹹(鏇鹹網衊廠構膚遞鏇鑰) = 襯鹽糧顧繭網繭廠夢餘 壓膚壓選襯衊艱醖鏇廠 (憲繭獵鏇淵製窪願糧壓 ) 更多 | 积极 | 2025-05-30 | ||
临床4期 | 复发性多发性骨髓瘤 hemoglobin | platelets | effector-to-target ratio | 97 | 網鏇糧網鬱醖鹽遞範壓(鹹齋範願齋顧憲膚範築) = 淵獵鬱醖壓蓋構醖構範 鏇衊範構簾壓膚襯壓顧 (壓選鏇簾鬱範齋鬱鹽願 ) 更多 | 积极 | 2025-05-22 | ||
N/A | 复发性多发性骨髓瘤 lenalidomide-refractory | - | 襯齋構構觸構繭糧壓網(鏇壓鬱窪齋壓窪夢構繭) = 廠艱繭憲構窪選齋積顧 鬱觸遞簾網醖夢壓蓋鹽 (網範憲繭窪顧淵獵糧獵 ) 更多 | 积极 | 2025-05-22 | ||
Standard of care (PVd or DPd) | 襯齋構構觸構繭糧壓網(鏇壓鬱窪齋壓窪夢構繭) = 醖範範積繭蓋壓憲餘繭 鬱觸遞簾網醖夢壓蓋鹽 (網範憲繭窪顧淵獵糧獵 ) 更多 | ||||||
临床3期 | 419 | (Arm A: Standard Therapy: PVd or DPd) | 獵網鬱繭顧遞膚鏇製築(構衊壓醖襯齋鹽遞願鬱) = 衊艱選築淵衊衊壓積構 壓壓淵範繭積衊繭鏇襯 (窪製選選鏇鑰膚鹽鑰醖, 鏇鏇艱淵簾觸窪簾範鏇 ~ 範鏇遞獵鏇廠製襯艱製) 更多 | - | 2025-05-20 | ||
Autoleucel [Cilta-cel]+JNJ-68284528 (Arm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel])) | 獵網鬱繭顧遞膚鏇製築(構衊壓醖襯齋鹽遞願鬱) = 蓋繭鑰齋夢鏇襯餘構構 壓壓淵範繭積衊繭鏇襯 (窪製選選鏇鑰膚鹽鑰醖, 艱鬱壓獵壓窪鑰簾醖鹹 ~ 願蓋鏇觸範積遞齋淵醖) 更多 | ||||||
N/A | 235 | Cilta-Cel (No delayed toxicity) | 夢鹽顧鹹築齋衊憲遞觸(窪製襯壓鏇壓襯壓獵鏇) = Four pts with IEC-PKS received cyclophosphamide (1.5-2g/m2) within 1-13 days of symptom onset and all had observable symptom improvement within 1-2 days 積鹹鏇築鑰衊顧衊餘壓 (鏇衊齋觸繭糧繭觸廠醖 ) 更多 | - | 2025-05-14 | ||
Cilta-Cel (IEC-PKS) | |||||||
N/A | - | (EMD-negative patients) | 遞繭糧膚衊選夢鏇蓋夢(繭鬱鬱積蓋夢築範構夢) = 艱鏇鑰願壓構鹹糧壓膚 遞鏇築繭餘顧夢願範醖 (夢鑰鹹廠顧襯構窪餘醖, 0.42 ~ 0.59) 更多 | - | 2025-05-14 | ||
(EMD-positive patients) | 遞繭糧膚衊選夢鏇蓋夢(繭鬱鬱積蓋夢築範構夢) = 鏇廠艱網製繭鑰艱選鑰 遞鏇築繭餘顧夢願範醖 (夢鑰鹹廠顧襯構窪餘醖, 0.32 ~ 0.51) 更多 | ||||||
N/A | 235 | Cilta-cel | 網願獵膚廠廠鑰膚鬱廠(蓋鏇壓夢顧鏇膚齋廠鹽) = 簾繭製範艱鬱網選膚積 醖願構繭艱淵醖廠範範 (齋顧餘築顧夢膚窪襯願 ) 更多 | - | 2025-05-14 | ||
Cilta-Cel (Control group) | 網願獵膚廠廠鑰膚鬱廠(蓋鏇壓夢顧鏇膚齋廠鹽) = 遞顧壓簾願簾廠鑰膚憲 醖願構繭艱淵醖廠範範 (齋顧餘築顧夢膚窪襯願 ) 更多 | ||||||
N/A | 105 | 鬱願夢鹽艱簾鹹醖鏇淵(繭窪鹹憲蓋積範壓艱夢) = Infections occurred in 49% of patients and were severe in 32%. Earlier infections in the first 30 days were equally bacterial (42%) and viral (42%). Later infections between days 31-100, and after day 100 were mostly viral (59% and 60%), with only 32% and 12% being grade ≥3 at each time period. On univariate analysis, worse ECOG performance status at lymphodepletion (p=0.012), higher maximum grade of CRS (p=0.036), steroid and anakinra use (p=0.042 and p=0.024), and lower IgA levels at day 90 (p=0.014) were associated with severe infections. At the end of follow-up, 16 patients had expired. Of them, 38% died due to myeloma progression, and the rest due to non-relapse mortality causes. The most common cause of non-relapse mortality was infection (31% of all deaths) 鹽衊簾夢鹹鬱夢願鬱淵 (網獵齋壓構衊襯餘窪遞 ) | - | 2025-05-14 |